DG Comp issues fresh pay-for-delay charge
The EU’s competition watchdog has accused drugmaker Teva and subsidiary Cephalon – a former rival – of signing an illegal patent settlement in which Teva agreed to delay the entry of a generic sleep disorder drug.
To read more
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.